Overview of COVID-19
Last Updated: December 1, 2022
Individuals of all ages are at risk for SARS-CoV-2 infection and severe disease. However, the probability of severe COVID-19 is higher in people aged ≥65 years, those living in a nursing home or long-term care facility, those who are not vaccinated against COVID-19 or who have poor responses to COVID-19 vaccines, and those with chronic medical conditions. Data on comorbid health conditions among patients with COVID-19 indicate that patients with cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes with complications, neurocognitive disorders, and obesity are at increased risk of severe COVID-19. The risk appears to be higher in patients with multiple comorbid conditions. Other conditions that may lead to a high risk of severe COVID-19 include cancer, cystic fibrosis, immunocompromising conditions, liver disease (especially in patients with cirrhosis), pregnancy, and sickle cell disease. Transplant recipients and people who are taking immunosuppressive medications may also have a higher risk of severe COVID-19.1 See Clinical Spectrum of SARS-CoV-2 Infection for a description of the clinical manifestations of SARS-CoV-2 infection and a discussion of the spectrum of disease.
Although COVID-19 vaccination does not eliminate the risk of SARS-CoV-2 infection, vaccination does significantly reduce the risk of COVID-19–related morbidity and mortality, particularly in individuals who are at high risk of progressing to severe disease.2,3 In individuals who may not be able to mount adequate responses to COVID-19 vaccines due to immunocompromising conditions or the receipt of immunosuppressive medications, the use of the anti-SARS-CoV-2 monoclonal antibodies (mAbs) tixagevimab plus cilgavimab (Evusheld) as pre-exposure prophylaxis (PrEP) can reduce the risk of breakthrough infection and improve clinical outcomes.4-6
Racial and Ethnic Minorities and Other Marginalized Groups
Communities that have been historically marginalized or made socially vulnerable due to a lack of access to health care or an inability to socially isolate are at increased risk of SARS-CoV-2 acquisition, COVID-19–related hospitalization, and death. These communities include racial and ethnic minorities, essential non-health care workers, and some people with disabilities.
- The COVID-19 Treatment Guidelines Panel (the Panel) recommends that health care providers, health care systems, and payers ensure equitable access to high-quality care and treatment for all patients, regardless of race, ethnic identity, or other minoritized identity or social status (AIII). “Minoritized” refers to social groups that have been deprived of power and status by the dominant culture in society and encompasses not just racial identities but other identities as well, including gender identity and sexual orientation.7
- Promoting equitable care for these groups must include considering the full range of medical, demographic, and social factors that may negatively impact health outcomes.
- Clinicians should also be aware that pulse oximeters may not accurately detect hypoxemia in people with darker skin pigmentation.8,9 This may delay treatment and lead to worse clinical outcomes in patients with COVID-19.10 See Clinical Spectrum of SARS-CoV-2 Infection for more information.
- Supporting equitable access to high-quality care and treatment for all groups is now an imperative for all Joint Commission-accredited health care organizations, as well as a priority for the Centers for Disease Control and Prevention (CDC) and other public health agencies.
COVID-19–Related Health Outcomes
Historical structural inequities significantly contribute to the health disparities experienced by racial and ethnic minority groups (e.g., Black/African American people, Hispanic people, American Indian/Alaska Native people).11 Recent data have highlighted that some racial and ethnic minority groups experience higher rates of COVID-19, subsequent hospitalization, and death in relation to their share of the total U.S. population. Black/African American people, Hispanic people, and American Indian/Alaska Native people also experience rates of hospitalization that are more than 2 times higher and rates of COVID-19-related death that are approximately 2 times higher than those experienced by White people. The largest disparities were observed among American Indian/Alaska Native people, who experienced a rate of hospitalization almost 3 times higher and a rate of death 2.1 times higher than White people.12
The increased risk of severe COVID-19 among racial and ethnic minority groups may be partly attributed to higher rates of comorbid conditions in these populations (e.g., cardiovascular disease, diabetes, chronic kidney disease, hypertension, obesity, pulmonary diseases).12
Disparities in Access to Care
Members of racial and ethnic minority groups have an increased risk of exposure to COVID-19 and decreased access to care. Large-scale mobility data reveals that people living in lower-income communities were less able to physically isolate during COVID-19 emergency declarations,13 as members of these communities were frequently unable to work from home.14 A 2020 study evaluated access to health care resources in New York City and found that in areas of the city where the majority of the population was Black/African American and Hispanic, there were higher COVID-19 positivity rates and fewer licensed hospital beds and intensive care unit beds than in areas where the majority of the population was White.15
Disparities in Access to COVID-19 Treatments
Data from 41 U.S. health care systems reveal racial and ethnic disparities in the use of anti-SARS-CoV-2 mAbs for the treatment of COVID-19.16 Black/African American patients, Asian patients, and patients of other races were, respectively, 22.4%, 48.3%, and 46.5% less likely to receive anti-SARS-CoV-2 mAbs for the treatment of COVID-19 than White patients.16,17 Disparities have also been observed in the dispensing rates for ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir. During the period when the use of outpatient COVID-19 medication was increasing substantially, treatment with ritonavir-boosted nirmatrelvir was 35.8% lower among Black/African American patients and 29.9% lower among Hispanic patients than among White patients.18 Despite a greater number of dispensing sites in neighborhoods with a higher social vulnerability, oral antivirals were prescribed at a lower rate for patients with COVID-19 who were living in these areas than in those with a lesser degree of social vulnerability.19 These disparities are not limited to outpatient settings. One retrospective cohort study of veterans hospitalized with COVID-19 reported that Black veterans had lower odds of receiving COVID-19–specific treatments, including systemic steroids, remdesivir, and immunomodulators, than White veterans.20
Other Marginalized Groups
Other marginalized groups also experience worse outcomes for COVID-19. Hospitalization rates for COVID-19 among Medicare beneficiaries who were eligible for disability were approximately 50% higher than those among people who were eligible for Medicare based on age alone, and this discrepancy disproportionately affected Black/African American people, Hispanic people, and American Indian/Alaska Native people.21
Migrants, refugees, and essential non-health care workers (e.g., food supply, food service, public transportation, and agricultural workers) also have disproportionately high rates of COVID-19 cases and deaths. These high rates can be attributed to overcrowding, an inability to physically isolate, and inadequate access to health care.22-24
Given the pervasiveness of disparities in access to care and provision of treatment, it is imperative for clinicians, working with others on the patient care team, to assess the social factors that contribute to access and quality gaps and to strive to provide equitable treatment to all patients. These issues have been identified as a strategic priority by the CDC and The Joint Commission.
Like other RNA viruses, SARS-CoV-2 is constantly evolving through random mutations. New mutations can potentially increase or decrease infectiousness and virulence. In addition, mutations can increase the virus’ ability to evade adaptive immune responses from past SARS-CoV-2 infection or vaccination. This viral evolution may increase the risk of reinfection or decrease the efficacy of vaccines.25 There is evidence that some SARS-CoV-2 variants have reduced susceptibility to plasma from people who were previously infected or immunized, as well as to certain anti-SARS-CoV-2 mAbs.26-28
Since December 2020, the World Health Organization (WHO) has assigned Greek letter designations to several identified variants. A SARS-CoV-2 variant designated as a variant of concern (VOC) displays certain characteristics, such as increased transmissibility or virulence. In addition, vaccines and therapeutics may have decreased effectiveness against VOCs, and the mutations found in these variants may interfere with the targets of diagnostic tests. The variant of interest (VOI) designation has been used for important variants that are not fully characterized; however, organizations do not use the same variant designations, and they may define their variant designations differently.29,30 In September 2021, the CDC added a new designation for variants: variants being monitored (VBM). This refers to variants for which data indicate a potential or clear impact on approved or authorized medical countermeasures or variants associated with more severe disease or increased transmission rates. However, these variants are either no longer detected or are circulating at very low levels in the United States; therefore, they do not pose a significant and imminent risk to public health in the United States.
The Omicron variant was designated a VOC in November 2021 and rapidly became the dominant variant across the globe. The Omicron subvariants BA.1, BA.1.1, and BA.2 emerged in early to mid-2022. The subvariants BA.4 and BA.5 and, more recently, other subvariants such as BA.2.75, BA.4.6, BF.7, BQ.1, and BQ.1.1 are circulating in the United States. The newer Omicron subvariants are more transmissible than other variants and are not susceptible to some of the anti-SARS-CoV-2 mAbs that have been developed for treatment and prevention.27,28,31,32
Earlier variants include the Alpha (B.1.1.7) variant, which was first seen in the United Kingdom and shown to be highly infectious and possibly more virulent than previously reported variants;33-35 the Beta (B.1.351) variant, which was originally identified in South Africa; the Gamma (P.1) variant, which was identified in Manaus, Brazil; and the Delta (B.1.617.2) variant, which was identified in India. Although the Alpha, Beta, Gamma, and Delta variants were previously designated as VOCs, they have largely disappeared worldwide. For a detailed discussion on the susceptibility of certain VOCs, VOIs, and VBMs to available anti-SARS-CoV-2 mAbs, please see Anti-SARS-CoV-2 Monoclonal Antibodies.
Data on the emergence, transmission, and clinical relevance of these new variants are rapidly evolving; this is especially true for research on how variants might affect transmission rates, disease progression, vaccine development, and the efficacy of current therapeutics. Because the research on variants is moving quickly and the classification of the different variants may change over time, websites such as the CDC’s COVID Data Tracker, CoVariants.org, and WHO’s Tracking SARS-CoV-2 Variants provide regular updates on data for SARS-CoV-2 variants. The Panel reviews emerging data on these variants, paying particular attention to research on the impacts of these variants on testing, prevention, and treatment.
- Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed October 27, 2022.
- Centers for Disease Control and Prevention. Rates of laboratory-confirmed COVID-19 hospitalizations by vaccination status. 2022. Available at: https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination. Accessed October 13, 2022.
- Our World in Data. United States: COVID-19 weekly death rate by vaccination status (before boosters). 2022. Available at: https://ourworldindata.org/grapher/united-states-rates-of-covid-19-deaths-by-vaccination-status-by-vaccine?country=12-17~12~12. Accessed November 30, 2022.
- Young-Xu Y, Epstein L, Marconi VC, et al. Tixagevimab/cilgavimab for prevention of COVID-19 during the Omicron surge: retrospective analysis of national VA electronic data. medRxiv. 2022;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2022.05.28.22275716v1.
- Al Jurdi A, Morena L, Cote M, et al. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the Omicron wave. Am J Transplant. 2022;22(12):3130-3136. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35727916.
- Kaminski H, Gigan M, Vermorel A, et al. COVID-19 morbidity decreases with tixagevimab-cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders. Kidney Int. 2022;102(4):936-938. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35870641.
- American Medical Association. Advancing health equity: a guide to language, narrative and concepts. 2021. Available at: https://ama-assn.org/equity-guide.
- Chesley CF, Lane-Fall MB, Panchanadam V, et al. Racial disparities in occult hypoxemia and clinically based mitigation strategies to apply in advance of technological advancements. Respir Care. 2022;67(12):1499-1507. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35679133.
- Valbuena VSM, Seelye S, Sjoding MW, et al. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013–19: multicenter, retrospective cohort study. BMJ. 2022;378:e069775. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35793817.
- Fawzy A, Wu TD, Wang K, et al. Racial and ethnic discrepancy in pulse oximetry and delayed identification of treatment eligibility among patients with COVID-19. JAMA Intern Med. 2022;182(7):730-738. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35639368.
- National Academies of Sciences, Engineering, and Medicine, Board on Population Health and Public Health Practice, Committee on Community-Based Solutions to Promote Health Equity in the United States. Communities in Action: Pathways to Health Equity. National Academies Press; 2017. Available at: https://pubmed.ncbi.nlm.nih.gov/28418632.
- Mackey K, Ayers CK, Kondo KK, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021;174(3):362-373. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33253040.
- Weill JA, Stigler M, Deschenes O, Springborn MR. Social distancing responses to COVID-19 emergency declarations strongly differentiated by income. Proc Natl Acad Sci U S A. 2020;117(33):19658-19660. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32727905.
- Economic Policy Institute. Not everybody can work from home. Black and Hispanic workers are much less likely to be able to telework. 2020. Available at: https://www.epi.org/blog/black-and-hispanic-workers-are-much-less-likely-to-be-able-to-work-from-home/. Accessed November 7, 2022.
- Douglas JA, Subica AM. COVID-19 treatment resource disparities and social disadvantage in New York City. Prev Med. 2020;141:106282. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33035550.
- Wiltz JL, Feehan AK, Molinari NM, et al. Racial and ethnic disparities in receipt of medications for treatment of COVID-19—United States, March 2020–August 2021. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35051133.
- Wu EL, Kumar RN, Moore WJ, et al. Disparities in COVID-19 monoclonal antibody delivery: a retrospective cohort study. J Gen Intern Med. 2022;37(10):2505-2513. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35469360.
- Boehmer TK, Koumans EH, Skillen EL, et al. Racial and ethnic disparities in outpatient treatment of COVID-19—United States, January–July 2022. MMWR Morb Mortal Wkly Rep. 2022;71(43):1359-1365. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36301738.
- Gold JAW, Kelleher J, Magid J, et al. Dispensing of oral antiviral drugs for treatment of COVID-19 by ZIP code-level social vulnerability—United States, December 23, 2021–May 21, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(25):825-829. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35737571.
- Castro AD, Mayr FB, Talisa VB, et al. Variation in clinical treatment and outcomes by race among US veterans hospitalized with COVID-19. JAMA Netw Open. 2022;5(10):e2238507. Available at: https://www.ncbi.nlm.nih.gov/pubmed/36282499.
- Yuan Y, Thierry JM, Bull-Otterson L, et al. COVID-19 cases and hospitalizations among Medicare beneficiaries with and without disabilities—United States, January 1, 2020–November 20, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(24):791-796. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35709015.
- Hayward SE, Deal A, Cheng C, et al. Clinical outcomes and risk factors for COVID-19 among migrant populations in high-income countries: a systematic review. J Migr Health. 2021;3:100041. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33903857.
- Lewnard JA, Mora AM, Nkwocha O, et al. Prevalence and clinical profile of severe acute respiratory syndrome coronavirus 2 infection among farmworkers, California, USA, June-November 2020. Emerg Infect Dis. 2021;27(5):1330-1342. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33657340.
- Heinzerling A, Vergara XP, Gebreegziabher E, et al. COVID-19 outbreaks and mortality among public transportation workers—California, January 2020–May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(33):1052-1056. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35980867.
- Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the United States—challenges and opportunities. JAMA. 2021;325(11):1037-1038. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33595644.
- Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130-135. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33684923.
- Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602(7898):664-670. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35016195.
- Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35016198.
- World Health Organization. Tracking SARS-CoV-2 variants. 2022. Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants. Accessed April 13, 2022.
- Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. 2022. Available at: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html. Accessed August 16, 2022.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab). 2022. Available at: https://www.fda.gov/media/154701/download.
- Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.
- Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021;26(1). Available at: https://www.ncbi.nlm.nih.gov/pubmed/33413740.
- Davies NG, Barnard RC, Jarvis CI, et al. Report: continued spread of VOC 202012/01 in England. 2020. Available at: https://cmmid.github.io/topics/covid19/reports/uk-novel-variant/2020_12_31_Transmissibility_and_severity_of_VOC_202012_01_in_England_update_1.pdf.
- Murugan NA, Javali PS, Pandianb CJ, Ali MA, Srivastava V, Jeyaraman J. Computational investigation of the increased virulence and pathogenesis of SARS-CoV-2 lineage B.1.1.7. Phys Chem Chem Phys. 2022;24(34):20371-20380. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35983778.